These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
225 related articles for article (PubMed ID: 30901730)
1. Characterization of the ERG-regulated Kinome in Prostate Cancer Identifies TNIK as a Potential Therapeutic Target. Lee RS; Zhang L; Berger A; Lawrence MG; Song J; Niranjan B; Davies RG; Lister NL; Sandhu SK; Rubin MA; Risbridger GP; Taylor RA; Rickman DS; Horvath LG; Daly RJ Neoplasia; 2019 Apr; 21(4):389-400. PubMed ID: 30901730 [TBL] [Abstract][Full Text] [Related]
2. Significance of the TMPRSS2:ERG gene fusion in prostate cancer. Wang Z; Wang Y; Zhang J; Hu Q; Zhi F; Zhang S; Mao D; Zhang Y; Liang H Mol Med Rep; 2017 Oct; 16(4):5450-5458. PubMed ID: 28849022 [TBL] [Abstract][Full Text] [Related]
3. A novel aminothiazole KY-05009 with potential to inhibit Traf2- and Nck-interacting kinase (TNIK) attenuates TGF-β1-mediated epithelial-to-mesenchymal transition in human lung adenocarcinoma A549 cells. Kim J; Moon SH; Kim BT; Chae CH; Lee JY; Kim SH PLoS One; 2014; 9(10):e110180. PubMed ID: 25337707 [TBL] [Abstract][Full Text] [Related]
4. ERG is a critical regulator of Wnt/LEF1 signaling in prostate cancer. Wu L; Zhao JC; Kim J; Jin HJ; Wang CY; Yu J Cancer Res; 2013 Oct; 73(19):6068-79. PubMed ID: 23913826 [TBL] [Abstract][Full Text] [Related]
5. TNIK inhibition abrogates colorectal cancer stemness. Masuda M; Uno Y; Ohbayashi N; Ohata H; Mimata A; Kukimoto-Niino M; Moriyama H; Kashimoto S; Inoue T; Goto N; Okamoto K; Shirouzu M; Sawa M; Yamada T Nat Commun; 2016 Aug; 7():12586. PubMed ID: 27562646 [TBL] [Abstract][Full Text] [Related]
6. Synergistic inhibition effect of TNIK inhibitor KY-05009 and receptor tyrosine kinase inhibitor dovitinib on IL-6-induced proliferation and Wnt signaling pathway in human multiple myeloma cells. Lee Y; Jung JI; Park KY; Kim SA; Kim J Oncotarget; 2017 Jun; 8(25):41091-41101. PubMed ID: 28467797 [TBL] [Abstract][Full Text] [Related]
7. Identification of TDRD1 as a direct target gene of ERG in primary prostate cancer. Boormans JL; Korsten H; Ziel-van der Made AJ; van Leenders GJ; de Vos CV; Jenster G; Trapman J Int J Cancer; 2013 Jul; 133(2):335-45. PubMed ID: 23319146 [TBL] [Abstract][Full Text] [Related]
8. Vitamin D receptor activation reduces VCaP xenograft tumor growth and counteracts ERG activity despite induction of TMPRSS2:ERG. Roberts JM; Martin RS; Piyarathna DB; MacKrell JG; Rocha GV; Dodge JA; Coarfa C; Krishnan V; Rowley DR; Weigel NL Oncotarget; 2017 Jul; 8(27):44447-44464. PubMed ID: 28591703 [TBL] [Abstract][Full Text] [Related]
9. TMPRSS2-ERG fusion protein regulates insulin-like growth factor-1 receptor (IGF1R) gene expression in prostate cancer: involvement of transcription factor Sp1. Meisel Sharon S; Pozniak Y; Geiger T; Werner H Oncotarget; 2016 Aug; 7(32):51375-51392. PubMed ID: 27285981 [TBL] [Abstract][Full Text] [Related]
11. Direct conversion of osteosarcoma to adipocytes by targeting TNIK. Hirozane T; Masuda M; Sugano T; Sekita T; Goto N; Aoyama T; Sakagami T; Uno Y; Moriyama H; Sawa M; Asano N; Nakamura M; Matsumoto M; Nakayama R; Kondo T; Kawai A; Kobayashi E; Yamada T JCI Insight; 2021 Feb; 6(3):. PubMed ID: 33400690 [TBL] [Abstract][Full Text] [Related]
12. Identification of a Small Molecule That Selectively Inhibits ERG-Positive Cancer Cell Growth. Mohamed AA; Xavier CP; Sukumar G; Tan SH; Ravindranath L; Seraj N; Kumar V; Sreenath T; McLeod DG; Petrovics G; Rosner IL; Srivastava M; Strovel J; Malhotra SV; LaRonde NA; Dobi A; Dalgard CL; Srivastava S Cancer Res; 2018 Jul; 78(13):3659-3671. PubMed ID: 29712692 [TBL] [Abstract][Full Text] [Related]
13. Traf2- and Nck-interacting kinase (TNIK) is involved in the anti-cancer mechanism of dovitinib in human multiple myeloma IM-9 cells. Chon HJ; Lee Y; Bae KJ; Byun BJ; Kim SA; Kim J Amino Acids; 2016 Jul; 48(7):1591-9. PubMed ID: 26995282 [TBL] [Abstract][Full Text] [Related]
14. Traf2- and Nck-interacting kinase is essential for Wnt signaling and colorectal cancer growth. Shitashige M; Satow R; Jigami T; Aoki K; Honda K; Shibata T; Ono M; Hirohashi S; Yamada T Cancer Res; 2010 Jun; 70(12):5024-33. PubMed ID: 20530691 [TBL] [Abstract][Full Text] [Related]
15. Loss of FOXO1 Cooperates with TMPRSS2-ERG Overexpression to Promote Prostate Tumorigenesis and Cell Invasion. Yang Y; Blee AM; Wang D; An J; Pan Y; Yan Y; Ma T; He Y; Dugdale J; Hou X; Zhang J; Weroha SJ; Zhu WG; Wang YA; DePinho RA; Xu W; Huang H Cancer Res; 2017 Dec; 77(23):6524-6537. PubMed ID: 28986382 [TBL] [Abstract][Full Text] [Related]
16. Discovery and characterization of small molecules targeting the DNA-binding ETS domain of ERG in prostate cancer. Butler MS; Roshan-Moniri M; Hsing M; Lau D; Kim A; Yen P; Mroczek M; Nouri M; Lien S; Axerio-Cilies P; Dalal K; Yau C; Ghaidi F; Guo Y; Yamazaki T; Lawn S; Gleave ME; Gregory-Evans CY; McIntosh LP; Cox ME; Rennie PS; Cherkasov A Oncotarget; 2017 Jun; 8(26):42438-42454. PubMed ID: 28465491 [TBL] [Abstract][Full Text] [Related]
17. Nuclear expression of phosphorylated TRAF2- and NCK-interacting kinase in hepatocellular carcinoma is associated with poor prognosis. Jin J; Jung HY; Wang Y; Xie J; Yeom YI; Jang JJ; Lee KB Pathol Res Pract; 2014 Oct; 210(10):621-7. PubMed ID: 25160513 [TBL] [Abstract][Full Text] [Related]
18. Traf2 and NCK Interacting Kinase Is a Critical Regulator of Procollagen I Trafficking and Hepatic Fibrogenesis in Mice. Buchl SC; Hanquier Z; Haak AJ; Thomason YM; Huebert RC; Shah VH; Maiers JL Hepatol Commun; 2022 Mar; 6(3):593-609. PubMed ID: 34677004 [TBL] [Abstract][Full Text] [Related]
19. The ubiquitin ligase TRIM25 targets ERG for degradation in prostate cancer. Wang S; Kollipara RK; Humphries CG; Ma SH; Hutchinson R; Li R; Siddiqui J; Tomlins SA; Raj GV; Kittler R Oncotarget; 2016 Oct; 7(40):64921-64931. PubMed ID: 27626314 [TBL] [Abstract][Full Text] [Related]